Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics' stock price has been impacted by several events. In October 2025, the company announced it would not pursue a broad label for Vafseo for non-dialysis dependent chronic kidney disease (NDD-CKD) patients. In February 2026, AKBA shares gained 9.1% following its Q4 2025 earnings announcement. The company's Q1 2026 earnings report on May 7, 2026, led to a significant stock drop of over 20% due to a net loss of $9.1 million and lower Auryxia sales. An increase in generic competition for Auryxia is expected to further reduce its revenues in 2026. Over the past year, the share price declined by 54.51%, and as of May 7, 2026, the stock had declined over 27% year-to-date.

There is no explicit information available regarding demand seasonality for Akebia Therapeutics' products and services.

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for kidney diseases. The company's portfolio includes two FDA-approved products: Auryxia for controlling serum phosphorus levels and treating iron deficiency anemia in chronic kidney disease patients, and Vafseo, a HIF-PH inhibitor approved in multiple countries for anemia due to chronic kidney disease. Akebia also has a pipeline of investigational products, including AKB-9090 in Phase 2 clinical trials for acute kidney injury and acute respiratory distress syndrome, AKB-10108 for retinopathy of prematurity, and praliciguat and AKB-097, which are also in Phase 2 trials.

Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries.

Information specifically detailing Akebia Therapeutics' brand reputation in terms of public perception, controversies, or positive recognition beyond financial and product development news for the past year is not readily available. The company's financial performance, including missed earnings and a significant stock drop in Q1 2026, could indirectly influence investor and market perception.

Akebia Therapeutics, Inc. has a diverse ownership structure. Institutional shareholders hold 44.08% of the stock, Akebia insiders own 8.14%, and retail investors account for 47.78%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and State Street Corp. BlackRock, Inc. is the largest shareholder with 7.1% of shares outstanding, followed by Vanguard Group Inc. with 5.9% and State Street Corp with 4.5%. The largest individual shareholder is Muneer A. Satter, who owns 5.04 million shares, representing 1.88% of the company.